Eric  Meissner  to  Sofosbuvir
                            
                            
                                This is a "connection" page, showing publications  Eric  Meissner  has written about  Sofosbuvir.
                            
                            
                            
                                
                                    
                                            
    
        
        
        
            Connection Strength
            
                
            
            2.204
         
        
        
     
 
    
        
        - 
            Peripheral blood correlates of virologic relapse after Sofosbuvir and Ribavirin treatment of Genotype-1 HCV infection. BMC Infect Dis. 2020 Dec 04; 20(1):929.
            
            
                Score: 0.703
             
- 
            Characterization of changes in intrahepatic immune cell populations during HCV treatment with sofosbuvir and ribavirin. J Viral Hepat. 2019 03; 26(3):323-328.
            
            
                Score: 0.612
             
- 
            Effects of ribavirin/sofosbuvir treatment and ITPA phenotype on endogenous purines. Antiviral Res. 2017 02; 138:79-85.
            
            
                Score: 0.133
             
- 
            Dynamic Changes of Post-Translationally Modified Forms of CXCL10 and Soluble DPP4 in HCV Subjects Receiving Interferon-Free Therapy. PLoS One. 2015; 10(7):e0133236.
            
            
                Score: 0.121
             
- 
            Serum and cellular ribavirin pharmacokinetic and concentration-effect analysis in HCV patients receiving sofosbuvir plus ribavirin. J Antimicrob Chemother. 2015 Aug; 70(8):2322-9.
            
            
                Score: 0.120
             
- 
            Effect of sofosbuvir and ribavirin treatment on peripheral and hepatic lipid metabolism in chronic hepatitis C virus, genotype 1-infected patients. Hepatology. 2015 Mar; 61(3):790-801.
            
            
                Score: 0.117
             
- 
            Endogenous intrahepatic IFNs and association with IFN-free HCV treatment outcome. J Clin Invest. 2014 Aug; 124(8):3352-63.
            
            
                Score: 0.113
             
- 
            IFNL4-?G genotype is associated with slower viral clearance in hepatitis C, genotype-1 patients treated with sofosbuvir and ribavirin. J Infect Dis. 2014 Jun 01; 209(11):1700-4.
            
            
                Score: 0.109
             
- 
            Interferon-Free Treatment of Hepatitis C Virus in HIV/Hepatitis C Virus-Coinfected Subjects Results in Increased Serum Low-Density Lipoprotein Concentration. AIDS Res Hum Retroviruses. 2016 May; 32(5):456-62.
            
            
                Score: 0.031
             
- 
            Four-Week Direct-Acting Antiviral Regimens in Noncirrhotic Patients With Hepatitis C Virus Genotype 1 Infection: An Open-Label, Nonrandomized Trial. Ann Intern Med. 2015 Dec 15; 163(12):899-907.
            
            
                Score: 0.031
             
- 
            Virologic response following combined ledipasvir and sofosbuvir administration in patients with HCV genotype 1 and HIV co-infection. JAMA. 2015 Mar 24-31; 313(12):1232-9.
            
            
                Score: 0.029
             
- 
            Virological response after 6 week triple-drug regimens for hepatitis C: a proof-of-concept phase 2A cohort study. Lancet. 2015 Mar 21; 385(9973):1107-13.
            
            
                Score: 0.029
             
- 
            Re-treatment of chronic hepatitis C virus genotype 1 infection after relapse: an open-label pilot study. Ann Intern Med. 2014 Nov 04; 161(9):634-8.
            
            
                Score: 0.029
             
- 
            Sofosbuvir and ribavirin for hepatitis C genotype 1 in patients with unfavorable treatment characteristics: a randomized clinical trial. JAMA. 2013 Aug 28; 310(8):804-11.
            
            
                Score: 0.027